2015: a good year for psoriasis drug development?
Psoriasis (PsO) is a chronic immune-mediated disease estimated to affect more than 125 million people worldwide.
Psoriasis (PsO) is a chronic immune-mediated disease estimated to affect more than 125 million people worldwide. The condition is characterised by thick and extensive skin lesions (plaques), which can cause itching, scaling, and pain. These symptoms can often negatively impact patients’ quality of life, both psychosocially and physically, making daily functioning more difficult and increasing the risk for other chronic illnesses. Although a number of treatment options exist for PsO, there continue to be significant unmet needs in the market
Driving Earlier Diagnosis: A Case Study in Psoriatic Arthritis
Mary Assimakopoulos, eyeforpharma 14th May 2013
Following a survey of 1000 Psoriatic Arthritis patients, Mary Assimakopoulos shares some of the root causes behind a late diagnosis of this debilitating illness, and the patients’ own feelings towards their standard of care. In this month’s column we discuss how promoting earlier diagnosis of a chronic disease, such as Psoriatic Arthritis (PsA), should result in better patient outcomes and generate a larger treatment market. PsA is an auto-immune disease which causes inflammation of the joints, pain and stiffness, which is accompanied by patches of red and white, scaly skin indicative of Psoriasis.PsA gets progressively worse and can cause permanent damage to the joints. These worsening skin manifestations can have a severe impact on a patient’s quality of life, particularly if located in highly visible parts of the body. Almost a third of people with psoriasis will develop PsA but patients may experience arthritic symptomsbefore any skin manifestations. The exact causes of the disease are not yet known, but a number of genetic associations have been identified. Because prolonged inflammation can lead to joint damage, early diagnosis and treatment is recommended and yet, in our patient research findings (carried out amongst people diagnosed with PsA across Europe), we have found…